Concepedia

Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer

Philip Bischoff, Martin Reck, Tobias R. Overbeck, Petros Christopoulos, Achim Rittmeyer, H Lüders, Jens Kollmeier, Jonas Kulhavy, Marcel Kemper, Niels Reinmuth,

Journal of Thoracic Oncology · 2023 · 48 citations · 37 references

DOIFull text

Open access

Concepts

References

37

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

Signatures of mutational processes in human cancer

Ludmil B. Alexandrov, Serena Nik‐Zainal, David C. Wedge et al. · Nature · 2013 · 10.1K citations · Full text

, , +14

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text

, , +17

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Robert Samstein, Chung‐Han Lee, Alexander N. Shoushtari et al. · Nature Genetics · 2019 · 4.4K citations · Full text

, , +14

The Effect of Advances in Lung-Cancer Treatment on Population Mortality

Nadia Howlader, Gonçalo Forjaz, Meghan J. Mooradian et al. · New England Journal of Medicine · 2020 · 1.7K citations · Full text

, , +16